Evidence map›Paper›PMID 31096735›Full record

ArticleCancer research and treatment2020

Disparities in the Participation Rate of Colorectal Cancer Screening by Fecal Occult Blood Test among People with Disabilities: A National Database Study in South Korea.

Dong Wook Shin, Dongkyung Chang, Jin Hyung Jung, Kyungdo Han, So Young Kim, Kui Son Choi, Won Chul Lee, Jong Heon Park, Jong Hyock Park

Abstract read
In one paragraph

Article in Cancer research and treatment, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Disability and Participation in Breast and Cervical Cancer Screening: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2022
    Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Enhancing doxorubicin's anticancer impact in colorectal cancer by targeting the Akt/Gsk3β/mTOR-SREBP1 signaling axis with an HDAC inhibitor.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dong Wook ShinDepartment of Family Medicine/Supportive Care Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Dongkyung ChangDepartment of Digital Health, SAIHST, Sungkyunkwan University, Seoul, Korea.
Jin Hyung JungDepartment of Medical Statistics, The Catholic University of Korea, Seoul, Korea.
Kyungdo HanDepartment of Medical Statistics, The Catholic University of Korea, Seoul, Korea.
So Young KimCollege of Medicine, Chungbuk National University/Chungbuk National University Hospital, Cheongju, Korea.
Kui Son ChoiDepartment of Cancer Control and Population Health, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea.
Won Chul LeeDepartment of Preventive Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Jong Heon ParkBig Data Steering Department, National Health Insurance Service, Wonju, Korea.
Jong Hyock ParkCollege of Medicine, Chungbuk National University/Chungbuk National University Hospital, Cheongju, Korea.

Funding

Korea National Rehabilitation Center Research InstituteMinistry of EducationMinistry of Health and WelfareMinistry of Science, ICT and Future Planning 2016R1A2B4011045National Research Foundation of Korea 2016R1D1A3B03931142
6 · The paper itself

Abstract

purposeImplementation of screening program may lead to increased health disparity within the population if participation differs by socioeconomic status. In Korea, colorectal cancer screening is provided at no or minimal cost to all people over 50 by National Cancer Screening Program. We investigated colorectal cancer screening participation rate and its trend over the last 10 years in relation to disabilities. MATERIALS AND

methodsWe linked national disability registration data with National Cancer Screening Program data. Age, sex-standardized participation rates were analyzed by type and severity of disability for each year, and factors associated with colorectal cancer screening participation were examined by multivariate logistic regression.

resultsAge, sex-standardized participation rate in people without disability increased from 16.2 to 33.9% (change, +17.7), but it increased from 12.7% to 27.2% (change, +14.5) among people with severe disability. People with severe disabilities showed a markedly lower colorectal cancer screening participation rate than people without disability (adjusted odds ratio [aOR], 0.714; 95% confidence interval, 0.713 to 0.720). People with autism (aOR, 0.468), renal failure (aOR, 0.498), brain injury (aOR, 0.581), ostomy (aOR, 0.602), and intellectual disability (aOR, 0.610) showed the lowest participation rates.

conclusionDespite the availability of a National Cancer Screening Program and overall increase of its usage in the Korean population, a significant disparity was found in colorectal cancer screening participation, especially in people with severe disabilities and or several specific types of disabilities. Greater effort is needed to identify the barriers faced by these particularly vulnerable groups and develop targeted interventions to reduce inequality.

Indexed as

Early Detection of CancerHealthcare DisparitiesOccult BloodPersons with DisabilitiesAgedAged, 80 and overColorectal NeoplasmsDatabases, FactualFemaleHumansMaleMass ScreeningMiddle AgedOdds RatioPublic Health SurveillanceRepublic of KoreaColorectal neoplasmsDisabilityFecal occult blood testKoreaScreening

Identifiers

PMID31096735
PMCPMC6962481

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.